Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Mayo Clinic
St. Jude Children's Research Hospital
Pheast Therapeutics
Centre Leon Berard
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Massachusetts General Hospital
Telix Pharmaceuticals (Innovations) Pty Limited
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Seattle Children's Hospital
Nationwide Children's Hospital
The New York Proton Center
Hoffmann-La Roche
Stemline Therapeutics, Inc.
Eastern Cooperative Oncology Group
Mayo Clinic
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Avera McKennan Hospital & University Health Center
Hoffmann-La Roche